
中国上海,2025年1月9日 —保诺-桑迪亚,一家值得信赖的全球化合同研究、开发和生产公司(CRDMO)今天宣布,其位于中国上海张江研发中心的全自动固相肽合成放大实验室正式启用。新的实验室进一步增强了公司的多肽合成能力,以满足全球合作伙伴对高效和可扩展性的多肽开发日益增长的需求。
新的公斤级多肽实验室配备了全自动固相肽合成仪、裂解仪和冻干设备,支持高达800毫摩尔的多肽固相合成。它可以支持多种多肽的合成及纯化服务,包括线性多肽、环状多肽和偶联肽(PDC)等。
该实验室与保诺-桑迪亚位于北京基地的多肽发现合成中心相辅相成,后者专注于早期研发,上海实验室则实现了多肽项目从发现到开发的无缝整合。两个基地的化学团队在固相和液相肽合成方面均有着丰厚经验,可以为客户提供更多的灵活性和定制化服务。
保诺-桑迪亚首席执行官Armin Spura博士表示:“随着多肽类药物研发热度的持续高涨,新实验室的开设为我们的客户在扩大候选药物规模,并迅速占领行业高地,迈出了重要一步。我们致力于不断提升CRDMO产能和服务效率,实现突破性进展,为全球患者提供改善生活的创新疗法。”
保诺-桑迪亚的多肽平台整合了生物学和药物代谢与动力学(DMPK)服务,提供一站式解决方案,以加速多肽药物开发。这种整合式的平台确保了流程精简以及高效协作,助力客户将创新多肽药物更快地推向市场。
“
关于保诺-桑迪亚
保诺-桑迪亚,安宏资本旗下投资企业,拥有29年的历史,是一家值得信赖的全球化合同研究、开发和生产公司(CRDMO)。公司总部位于加州尔湾,在中国和美国设有7个研发生产中心,在全球拥有2000多名员工。我们专注于小分子和大分子的药物发现、开发、放大和生产服务,为生物技术和制药企业提供从早期靶点确证到商业化生产的整合服务,涵盖化学、生物学、药代动力学、原料药和成品药等多个领域。保诺-桑迪亚专注CRDMO服务,在全球化质量标准体系下运营,提供先进、快速和灵活的定制服务,以满足生物技术和制药企业的专属需求,加快新药开发进程。
更多信息,请访问公司官网 www.bioduro-sundia.cn
IRVINE, CALIF., January 9, 2025 – BioDuro, a leading Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of a fully-automated solid-phase peptide synthesis scale-up laboratory at its Shanghai Zhangjiang High-tech Park campus in China. This new facility further enhances the company’s peptide synthesis capabilities to meet increasing demand from its global partners for efficient and scalable peptide manufacturing.
The state-of-the-art kilogram-scale peptide laboratory is equipped with automated solid phase peptide synthesizers, cleavage systems and freeze-drying equipment, supporting peptide synthesis scale up to 800 mmol. It is designed to produce a wide range of peptide molecules, including linear peptides, cyclic peptides, and various peptide drug conjugates (PDC).
Complementing BioDuro’s peptide discovery synthesis center at its Beijing campus, where the focus is on early-stage research and development, the Shanghai laboratory enables seamless integration of peptide projects from discovery to development. The chemistry teams at both campuses specialize in solid-phase and liquid-phase peptide synthesis, providing additional flexibility and customization for clients.
“Demand for peptide based programs has increased considerably, and the opening of this new laboratory provides BioDuro’s customers with a significant step forward in addressing the capabilities required to scale their candidates to compete in this fast-growing field,” commented Dr. Armin Spura, CEO of BioDuro. “We remain committed to continuously advancing our CRDMO capabilities and capacity, driving breakthroughs that deliver life-changing therapies to patients worldwide.”
BioDuro’s comprehensive peptide platform integrates biology and Drug Metabolism and Pharmacokinetics (DMPK) services, offering a one-stop shop solution to accelerate peptide development. This integrated approach is intended to ensure streamlined processes and efficient collaboration, helping clients bring innovative peptide therapeutics to market faster.
“
About BioDuro
BioDuro, an Advent International portfolio company, is a CRDMO with a 28-year proven track record. Headquartered in Irvine, California, USA, our global presence spans 7 sites across the United States and China, with over 2,000 employees. Specializing in both small and large molecule discovery, development, scale-up, and manufacturing, we offer fully integrated services from early drug discovery to commercial manufacturing across chemistry, biology, DMPK, drug substance, and drug product.
For more information, please visit https://www.bioduro.com
上海外高桥 | 上海张江 | 美国加州 | 无锡 | 河北 | 北京 | 蚌埠
从原料药到药品,从发现到开发,从小分子到生物制剂,保诺-桑迪亚是您的合作伙伴,可加快您的项目并提高候选药物成功的效率。
收藏
登录后参与评论